Table 5.
Median eGFR in patients treated with HU, RUX, or anagrelide/IMIDs/interferon.
| Sample (n = 1215) | Therapy | n (%) | eGFR mL/min/1.73 m2 | P | |||
|---|---|---|---|---|---|---|---|
| Median | Q1 | Q3 | Overall | Pairwise * | |||
| All patients (n = 1215) | <0.0001 | ||||||
| HU only | 256 (21.07) | 71.90 | 60.58 | 84.39 | 0.0005 | ||
| RUX only | 94 (7.74) | 68.56 | 56.23 | 84.48 | 0.0002 | ||
| Other | 341 (28.07) | 72.77 | 57.40 | 85.95 | |||
| Multiple therapies | 250 (20.58) | 71.00 | 54.41 | 84.62 | 0.0021 | ||
| WW | 524 (43.13) | 77.81 | 66.48 | 90.23 | |||
| ET (n = 471) | 0.0013 | ||||||
| HU only | 88 (18.68) | 72.43 | 63.26 | 86.72 | 0.0168 | ||
| RUX only | 5 (1.06) | 60.79 | 58.00 | 61.52 | 0.0588 | ||
| Other | 148 (31.42) | 76.70 | 57.48 | 89.24 | |||
| Multiple therapies | 88 (18.68) | 74.37 | 55.71 | 89.24 | >0.9999 | ||
| WW | 230 (48.83) | 78.55 | 69.47 | 91.42 | |||
| PV (n = 395) | 0.6865 | ||||||
| HU only | 135 (34.18) | 72.88 | 60.43 | 84.79 | 0.3516 | ||
| RUX only | 11 (2.78) | 72.21 | 55.75 | 81.59 | 0.8951 | ||
| Other | 90 (22.78) | 72.63 | 59.32 | 89.69 | |||
| Multiple therapies | 77 (19.49) | 70.11 | 58.69 | 83.20 | 0.3453 | ||
| WW | 159 (40.25) | 74.36 | 63.05 | 87.20 | |||
| MF (n = 349) | 0.0073 | ||||||
| HU only | 33 (9.46) | 68.90 | 58.61 | 73.45 | 0.0488 | ||
| RUX only | 78 (22.35) | 68.85 | 56.23 | 84.69 | 0.0188 | ||
| Other | 103 (29.51) | 69.74 | 53.46 | 81.02 | |||
| Multiple therapies | 85 (24.36) | 69.74 | 52.67 | 80.35 | 0.2208 | ||
| WW | 135 (38.68) | 76.29 | 62.46 | 91.20 | |||
* Therapy compared to WW. Bolded values indicate significant p values.